73792-06-0

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 4-AMINO-2-FLUOROBENZOATE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure, featuring both an amino and a fluorine atom, allows it to be a key component in the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 4-AMINO-2-FLUOROBENZOATE is utilized as an intermediate in the production of agrochemicals. Its role in this industry is crucial for the synthesis of compounds that can be used in the development of pesticides and other agricultural chemicals to protect crops and enhance yield.

InChI:InChI=1/C9H10FNO2/c1-2-13-9(12)7-4-3-6(11)5-8(7)10/h3-5H,2,11H2,1H3

Upstream product

• 363-32-6 2-fluoro-4-nitrobenzoic acid ethyl ester 
• 403-23-6 2-fluoro-4-nitrobenzoyl chloride 
• 64-17-5 ethanol 
• 1427-07-2 2-fluoro-4-nitrotoluene 
• 403-24-7 2-fluoro-4-nitrobenzoic acid 

Downstream Products

• 73792-07-1 2-Fluoro-4-hexadecylamino-benzoic acid ethyl ester 
• 191469-57-5 ethyl 2-fluoro-4-[(3'-methoxymethoxy-4-bromo-5',6',7',8'-tetrahydro-5',5',8',8'-tetramethylnaphtalen-2'-yl)carbamoyl]benzoate 
• 188888-45-1 ethyl 2-fluoro-4-[[(5,6-dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl)carbonyl]amino]-benzoate 
• 192762-73-5 ethyl 2-fluoro-4-[[[8-bromo-2,2-dimethyl-4-(4-methylphenyl)-6-chromanyl]carbonyl]amino]benzoate 
• 73792-10-6 2-Fluoro-4-hexadecylamino-benzoic acid 
• 191469-02-0 Ethyl-2-fluoro-4-[(5',6',7',8'-tetrahydro-5',5',8',8'-tetramethylnaphtalen-2'-yl)carbamoyl]benzoate 
• 856253-98-0 4-[3-(8-ethynyl-2,2,4,4-tetramethyl-chroman-6-yl)-ureido]-2-fluoro-benzoic acid ethyl ester 
• 167549-34-0 ethyl 4-(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino)-2-fluorobenzoate 
• 1456693-26-7 8-(((tert-butyldiphenylsilyl)oxy)methyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydropyrazino[1,2-a]indole 
• 1456693-27-8 8-(((tert-butyldiphenylsilyl)oxy)methyl)-1-isopropyl-7-(methyl sulfonyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indole 
• 1456704-56-5 (R)-(1-isopropyl-7-(methylsulfonyl)-2-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,4-tetrahydropyrazino[1,2-a]indol-8-yl)methanol 
• 1456704-57-6 (S)-(1-isopropyl-7-(methylsulfonyl)-2-(4-(trifluoromethyl)pyrimidin-2-yl)-1,2,3,4-tetrahydropyrazino[1,2-a]indol-8-yl)methanol 
• 1456693-16-5 ethyl 4-amino-5-iodo-2-(methylthio)benzoate 

Relevant academic research and scientific papers

RAR-ALPHA COMPOUNDS FOR INFLAMMATORY DISEASE AND MALE CONTRACEPTION

Modulators of retinoid acid receptor-alpha (RARα) of formula (I) are provided herein, as well as pharmaceutical compositions and methods relating thereto.

RETINOID COMPOUND AND PHARMACEUTICAL COMPOSITION

PROBLEM TO BE SOLVED: To provide a novel retinoid compound that is low in teratogenicity, and a pharmaceutical composition containing said retinoid compound. SOLUTION: Provided are a retinoid compound which is a compound represented by the following formula (1) or a salt thereof, and a pharmaceutical composition containing said retinoid compound. In the formula, R1 represents a halogen atom, and R2 and R3 each independently represent a silyl group. SELECTED DRAWING: None COPYRIGHT: (C)2020,JPOandINPIT

Synthesis and cardiac imaging of 18F-ligands selective for β1-adrenoreceptors

A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/ β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.

Novel indolyl derivatives which are L-CPT1 inhibitors

The invention is concerned with novel heterobicyclic derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, A, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Novel sulfonamides as L-CPT1 inhibitors

The invention is concerned with novel sulfonamide derivatives of formula (I) wherein R2, R3, R4, A, X, Y1, Y2, Y3, Y4 and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

New enzymes and prodrugs for ADEPT

The present invention relates to nucleic acid molecules encoding mutant human carboxypeptidase A enzymes, and encoding conjugates of targeting molecules and mutant human carboxypeptidase A enzymes. The invention further relates to vectors and cell lines containing such nucleic acid molecules.

Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity

Compounds of the formula wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.

Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity

Compounds of the formula where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid inverse agonist type biological activity.